Strides Pharma Science Limited has informed the Exchange regarding a press release dated September 06, 2024, titled "Strides receive USFDA approval for Theophylline Extended-Release Tablets, 300 mg and 450 mg".
Strides Pharma Science Limited has informed the Exchange regarding a press release dated September 06, 2024, titled "Strides receive USFDA approval for Theophylline Extended-Release Tablets, 300 mg and 450 mg".